DOCSLIB.ORG

Zopiclone Produces Effects on Human Performance Similar to Flurazepam, Lormetazepam and Triazolam

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Zopiclone Produces Effects on Human Performance Similar to Flurazepam, Lormetazepam and Triazolam Br. J. clin. Pharmac. (1986), 21, 647-653 Zopiclone produces effects on human performance similar to flurazepam, lormetazepam and triazolam A. N. GRIFFITHS', D. M. JONES2 & A. RICHENS1 'Department of Pharmacology and Therapeutics, University of Wales College of Medicine, Cardiff and 2Department of Applied Psychology, University of Wales Institute of Science and Technology, Cardiff 1 The cognitive function and psychomotor performance of 10 healthy male volunteers were measured following single oral doses of: zopiclone (7.5 mg), flurazepam (15 mg), lormetazepam (1 mg), triazolam (0.25 mg) and placebo. 2 The performance tests selected (stroop task, five choice serial reaction time, memory span, logical reasoning, mood and saccadic eye movement analysis) were thought to reflect aspects of normal daily activity. 3 The tests demonstrated a clear reduction of performance for all active treatments. No drug emerged as the most potent sedative overall, as each of the tests was affected to a different degree by each drug. 4 Drug effects were not qualitatively different between active treatments so that zopi- clone was indistinguishable from the three benzodiazepines with which it was compared. Keywords zopiclone benzodiazepines human performance saccadic eye movements Introduction Zopiclone is a cyclopyrrolone derivative which, (7.5 mg) has been shown to be effective as an although structurally unrelated to the benzodia- hypnotic (Wickstrom & Giercksky, 1980), zepines, shares their pharmacological profile. and furthermore, Lader & Denney (1983) Binding studies have shown that zopiclone binds reported this dose to be the preferred hypnotic to brain benzodiazepine receptors but is not dose. recognised by peripheral (renal) benzodiazepine The marketed benzodiazepines selected for receptors. Blanchard et al. (1983) investigating use in this study provided a cross section of the modulating action of GABA and barbiturates elimination half-lives varying from the very short on zopiclone binding have shown differences 2 h half-life of triazolam through lormetazepam between zopiclone and benzodiazepines. They with a 9-15 h half-life to flurazepam whose active suggest that zopiclone may bind, in rat brain, to metabolite, N-desalkylflurazepam, has a half- sites that do not correspond exactly to the ben- life of 65 h. Doses were selected with reference zodiazepine sites. This was confirmed by Trifilletti to those recommended by the manufacturers. & Snyder (1984) who reported that zopiclone The present study used the effects of the drugs bound to a novel site linked allosterically to on saccadic eye movements as a measurement benzodiazepine receptors. of the time course of sedative drug action. In man zopiclone is well tolerated and is rapidly This approach has been previously reported and efficiently absorbed (> 75%). The plasma (Bittencourt et al., 1981, Tedeschi et al., 1983). kinetics of zopiclone are generally well described Into this framework, specific tasks of cognitive by a two compartment open model with a half and psychomotor performance have been fitted life of 5-6 h (Houghton etal., 1984); a large total to provide a more detailed insight into the nature body clearance of 300 ml min7l and a low renal of the induced sedation. clearance of 10 ml min-' (Gaillot et al., 1983). The aim of the study was to compare the The dose of zopiclone selected for this study effect of zopiclone with three marketed 647 648 A. N. Griffiths et al. benzodiazepines using a battery of tasks to The Stroop test assess psychomotor and cognitive performance. This test measured the time taken to read a colour word when printed in an incongruous ink. Methods For example, the word 'green' might be printed in red ink. The task of the subject was to give the Protocol response 'red' even though the natural and com- pelling tendency was to give the colour word Ten male volunteers aged 20-22 years of age 'green'. The time taken to make the response to were recruited. All were declared healthy after a a number of such items arranged on a card is full medical examination and had normal usually considerably longer than to a similar haematological and blood biochemical screening number of colour words which do not involve tests both before and after the study. The treat- such conflict. The task is thought to measure the ments, zopiclone (7.5 mg), flurazepam (15 mg), degree to which the individual is able to suppress lormetazepam (1 mg), triazolam (0.25 mg) and the conflict between the two types of response. placebo, were matched for size, shape and colour The effect of a drug on these response times by encapsulation. They were administered in a might be due to the effects on the speed of random order (using a conjugate latin square) reading rather than on the interference per se. and in a double-blind manner. Treatments were To control for this possibility, two other types of separated by at least 7 days. Volunteers were material were also presented along with the instructed to abstain from ethanol and caffeinated interfering material (the CW card). Their beverages for 24 h and 12 h respectively before purpose was to give some indication of any effects treatment and throughout treatment days. On on reading speed. In one (the W card), colour test days volunteers reported to the department words were presented in black ink on a white at 08.00 h, drug intake was at approximately background. In the other (the C card), patches 09.30 h. A standard diet was provided for of colour (of the same size as the material on the volunteers on test days. Volunteers were asked CW card) were presented. This gave a measure to perform the task battery before drug admini- of the speed of colour naming. stration and 1, 4 and 10 h after. Saccadic eye The version of this test used consisted of three movements were measured before and 0.5, 1, 2, cards (C, W and CW); each arranged in a 10 x 10 3, 4, 6, 8 and 10 h after drug intake. matrix of colours or colour words as appropriate. The study was granted ethical approval by the The colour names (four colours) used were red, Joint Ethics Committee, University of Wales green, yellow and blue, these being the least College of Medicine. Written informed consent, ambiguous in their naming. For the CW card witnessed by an independent person, was ob- each of the four colour words was represented tained from each volunteer. on a roughly equal number of occasions in each colour. Subjects were asked to name colours Saccadic eye movements aloud as quickly as possible and to read each card in a systematic fashion from left to right. Saccadic eye movements are rapid conjugate For each card the total time to read the hundred shifts of gaze, the dynamics of which are con- items and the number of errors were noted. trolled by groups of neurones situated in the brain stem. Peak saccade velocity has been Logical reasoning shown to be a good marker ofdrug induced CNS depression. Drug effects in normal volunteers This task measured performance at a relatively have been observed with barbiturates, opiates, high level of abstraction (Baddeley, 1968). On benzodiazepines, carbamazepine, amphetamine each trial subjects were presented with, first, a and ethanol (Griffiths et al., 1984). statement of a relation between two objects (for Volunteers were instructed to follow the move- example, 'A follows B'), which was followed by ments of a target presented to them on a televi- an exemplar ('AB'). The subject was asked to ion screen. Their eye movements were recorded decide whether each statement was true or false by electro-oculography. The target moved hori- (the case just given is, of course, false). Other zontally through a sequence of jumps of 30°40' more complex instances included 'A does not amplitude, with respect to the volunteer's nasion. precede B' and 'B is preceded by A'. A total Subsequently computer analysis of the recorded of twenty five trials were given on each occa- eye movements was carried out by a method sion and performance was measured in terms of described elsewhere (Griffiths etal., 1984). Each total time to perform all trials and number of measurement session lasted 3 min. errors. Zopiclone and human performance 649 All the materials were presented and Memory span the responses timed and scored on a micro- computer. The test was composed of strings of consonants presented individually on the screen of the Serial reaction microcomputer at a rate of one item per second. The length of each list was between 20 and 40 Subjects were required to make a speeded letters. Each list ended unpredictably. In this response to an unpredictable sequence of signals. way, subjects were unable to recruit themselves The task consisted of a display board with five to concentrate for a relatively short period as lights (light emitting diodes) mounted in the they might with a list of fixed length. In each shape of a pentagon. The display board was experimental session twenty lists were presented. inclined at approximately 400 to the horizontal Two versions of the list were deployed over the and immediately behind the response board. period of the experiment to minimize learning of Keys on the response board were arranged in a the lists. pentagonal pattern identical to the layout of the The subjects were asked to write down as lights on the display board. The subject was many as they could ofthe last few items in the list required to press the key on the response board after the list was stopped. Emphasis was placed corresponding to the position of the illuminated on reporting the items in the correct order on a light on the display board. Only one light was response blank which was provided for each illuminated at a time.
Load more

Recommended publications
  • Uso Adecuado De BZD En Insomnio Y Ansiedad.Pdf
    Vol. 6 Nº 1 · OCTUBRE 2014 BOLETÍN CANARIO DE USO RACIONAL DEL MEDICAMENTO DEL SCS Uso adecuado de BENZODIAZEPINAS en insomnio y ansiedad. SUMARIO PERFIL FARMACOLÓGICO DE LAS BZD (Tabla 1). - INTRODUCCIÓN 1 - PERFIL FARMACOLÓGICO DE LAS BENZODIAZEPINAS 1 No todas las BZD son iguales, ni tienen las mismas indicaciones. - BENZODIAZEPINAS EN EL INSOMNIO 2 Conocer algunos aspectos sobre su perfil farmacológico es esencial para realizar una prescripción adecuada y segura. - BENZODIAZEPINAS EN LA ANSIEDAD 4 - RECOMENDACIONES PARA SUSPENDER 5 Por lo general las BZD se absorben muy bien por vía oral, mientras TRATAMIENTOS CON BZD que la vía intramuscular presenta una absorción lenta e irregular, por - BIBLIOGRAFÍA 7 lo que no suele ser muy recomendada. En situaciones de emergencia (convulsiones) es preferible utilizar la vía endovenosa. INTRODUCCIÓN Inicio de acción y vida media: el inicio de acción es distinto según el principio activo y constituye un criterio fundamental en la selección de Las benzodiazepinas (BZD) son psicofármacos que actúan aumentan- las BZD. Puede ser: de inicio rápido (0,5-1 h), de utilidad en el insomnio do la acción del ácido gammaaminobutírico (GABA), principal neuro- de conciliación y en crisis de ansiedad; de inicio intermedio (1-3 h) o transmisor inhibidor del sistema nervioso central. Tienen indicaciones de inicio lento (> 3 h), preferibles en insomnio de mantenimiento o terapéuticas diversas, y auque su uso más habitual es en el tratamien- despertar precoz y en la ansiedad generalizada. to de la ansiedad e insomnio, también se utilizan en la inducción a la anestesia, en el tratamiento de las crisis comiciales, en el síndrome La vida media de las BZD es otro de los criterios de selección y puede 5 de abstinencia alcohólica, como tratamiento coadyuvante de de dolor ser : corta (< 6 h); intermedia (6-24 h) y larga (> 24 h).
    [Show full text]
  • Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam
    Early Morning Insomnia, Daytime Anxiety, and Organic Mental Disorder Associated with Triazolam Tjiauw-Ling Tan, MD, Edward 0. Bixler, PhD, Anthony Kales, MD, Roger J. Cadieux, MD, and Amy L. Goodman, MD Hershey, Pennsylvania A psychiatric syndrome characterized by agita­ Sleep Disorders Clinic. He began taking triazolam tion, paranoid ideation, depersonalization, and de­ at bedtime in a 0.5-mg dose eight months before pression, as well as paresthesias and hyperacusis, his referral. Although the drug was effective ini­ has been attributed to administration of triazolam tially, tolerance developed, causing the patient to (Halcion).1 The occurrence of these reactions led gradually increase the dosage until eventually he to the removal of the drug from the market in the was taking a total of 1.5 mg nightly. Netherlands. Isolated behavioral side effects that The physical examination revealed no contribu­ include amnesia2-4 and hallucinations5 have also tory conditions. However, assessment of the pa­ been reported with administration of triazolam. tient’s mental status revealed that he was extreme­ Rebound insomnia6 and early morning insom­ ly guarded and suspicious and preoccupied with nia,7 both associated with increases in daytime his sleeplessness to the degree that this hypochon­ anxiety,7,8 are withdrawal syndromes known driacal concern had a delusional quality. He also to occur with rapidly eliminated benzodiazepine described two episodes indicating memory impair­ hypnotics such as triazolam. Rebound insomnia ment; both incidents occurred in the late afternoon consists of a marked increase in wakefulness and involved preparing to eat certain foods, which above baseline levels following drug withdrawal.
    [Show full text]
  • Withdrawing Benzodiazepines in Primary Care
    PC\/ICU/ ADTiriC • CNS Drugs 2009,-23(1): 19-34 KtVltW MKIIWLC 1172-7047/I»/O(X)1«119/S4W5/C1 © 2009 Adis Dato Intocmation BV. All rights reserved. Withdrawing Benzodiazepines in Primary Care Malcolm Luder} Andre Tylee^ and ]ohn Donoghue^ 1 Institute of Psychiatry, King's College London, London, England 2 John Moores University, Liverpool, Scotland Contents Abstract ' 19 1. Benzodiazepine Usage 22 2. Interventions 23 2.1 Simple interventions 23 2.2 Piiarmacoiogicai interventions 25 2.3 Psychoiogical Interventions 26 2.4 Meta-Anaiysis ot Various interventions 27 3. Outcomes 28 4. Practicai Issues 29 5. Otiier Medications 30 5.1 Antidepressants 30 5.2 Symptomatic Treatments 30 6. Conciusions 31 Abstract The use of benzodiazepine anxiolytics and hypnotics continues to excite controversy. Views differ from expert to expert and from country to country as to the extent of the problem, or even whether long-term benzodiazepine use actually constitutes a problem. The adverse effects of these drugs have been extensively documented and their effectiveness is being increasingly questioned. Discontinua- tion is usually beneficial as it is followed by improved psychomotor and cognitive functioning, particularly in the elderly. The potential for dependence and addic- tion have also become more apparent. The licensing of SSRIs for anxiety disorders has widened the prescdbers' therapeutic choices (although this group of medications also have their own adverse effects). Melatonin agonists show promise in some forms of insomnia. Accordingly, it is now even more imperative that long-term benzodiazepine users be reviewed with respect to possible discon- tinuation. Strategies for discontinuation start with primary-care practitioners, who are still the main prescdbers.
    [Show full text]
  • Drug Class Review Newer Drugs for Insomnia
    Drug Class Review Newer Drugs for Insomnia Final Update 2 Report October 2008 The Agency for Healthcare Research and Quality has not yet seen or approved this report. The purpose of Drug Effectiveness Review Project reports is to make available information regarding the comparative clinical effectiveness and harms of different drugs. Reports are not usage guidelines, nor should they be read as an endorsement of or recommendation for any particular drug, use, or approach. Oregon Health & Science University does not recommend or endorse any guideline or recommendation developed by users of these reports. Update 1: July 2006 Original: December 2005 Susan Carson, MPH Marian S. McDonagh, PharmD Sujata Thakurta, MPA:HA Po-Yin Yen, MS Drug Effectiveness Review Project Marian McDonagh, PharmD, Principal Investigator Oregon Evidence-based Practice Center Mark Helfand, MD, MPH, Director Copyright © 2008 by Oregon Health & Science University Portland, Oregon 97239. All rights reserved. Final Report Update 2 Drug Effectiveness Review Project The medical literature relating to the topic is scanned periodically (see http://www.ohsu.edu/xd/research/centers-institutes/evidence-based-policy- center/derp/documents/methods.cfm for scanning process description). Upon review of the last scan, the Drug Effectiveness Review Project governance group elected not to proceed with another full update of this report based on the information contained in the scan. Some portions of the report may not be up to date. Prior versions of this report can be accessed at the DERP website. Insomnia Page 2 of 87 Final Report Update 2 Drug Effectiveness Review Project TABLE OF CONTENTS INTRODUCTION ............................................................................................................. 6 Scope and Key Questions ......................................................................................................................
    [Show full text]
  • Strategisk Regnskabsanalyse Og Værdiansættelse Af H. Lundbeck A/S
    Copenhagen Business School Hovedopgave 2011 Institut for Regnskab HD-R (Regnskab og og Revision Økonomistyring) Strategisk regnskabsanalyse og værdiansættelse af H. Lundbeck A/S Vejleder: Udarbejdet af: Ole Sørensen Mikael Thaarup Robertsen Institut for Regnskab og Revision Cpr. nr. 300880-XXXX Copenhagen Business School Afleveret 16. maj 2011 EXECUTIVE SUMMARY H. Lundbeck A/S is an international pharmaceutical company focused on development and marketing of treatment for diseases within the central nerve system (CNS). Lundbeck has in the last few years had an outstanding financial performance, but in the same period the value of the company’s stock are at a historical low. On top of that the largest Nordic bank Nordea had a sell recommendation and a target price of 85 DKK as late as end of 2010. Has the sell recommendation and the low target price a justification due to the fact that Lundbeck’s blockbuster product Cipralex®/Lexapro® will lose patent protection in 2012 in the US and 2014 in the remaining of the world? The derived objective of the thesis has been to create a reliable valuation of Lundbeck taking into account the current business, including products and research pipeline, the historic financial performance and the financial outlook for the future. The objective of the strategic analysis has been to obtain the required knowledge about the business, the industry and the society that all influence the future growth scenario. The conclusion on this underlying strategic analysis was that the industry is under pressure from both public health service providers and generic competitors. At the same time the potential marked for CNS products is increasing due to demographic changes and increasing income levels in more recent developed countries.
    [Show full text]
  • Triazolam (Halcion®) Instructions
    Mark Sebastian, DMD 33516 Ninth Ave. South, #2 Federal Way, WA 98003 (253) 941-6242 --or -- (253) 952-2005 [email protected] www.MarkSebastianDMD.com Triazolam (Halcion®) instructions If prescribed, take the diazepam (Valium®) pill just before bed the night before your dental surgery for a better night’s sleep. If you take other sleeping medications, take those instead of the diazepam (Valium®). Do not mix the two. If you have a morning appointment, you should to fast from solid foods after midnight. If you have an afternoon appointment, have a light breakfast. Unless you have a medical reason to eat (diabetic, etc.), do not eat anything for 6 hours before your appointment time. Water, apple juice, and black decaffeinated coffee/tea are OK for 3 hours before your appointment. Triazolam (Halcion®) is absorbed better on an empty stomach. Do not take caffeine or sugar) for 3 hours before your appointment, as all are stimulants that decrease the effectiveness of triazolam (Halcion®). No tobacco use for 8 hours before, as it is a stimulant. Take the triazolam (Halcion®) or diazepam (Valium®) pill(s) with a glass of water. Sparkling water makes them absorb better. Alcohol---do not drink within 24 hours before to 24 hours after taking triazolam (Halcion®) or diazepam (Valium®). Recreational/illegal drugs---Do not use for 7 days before your dental surgery and until 7 days after (never if you are taking narcotic pain medication). Example—using cocaine and then having local anesthetics (novocaine) can kill you. Do not take triazolam (Halcion®) or diazepam (Valium®) if you are allergic to triazolam (Halcion®), alprazolam (Xanax®), chlordiazepoxide (Librium®, Librax®), clonazepam (Klonopin®), clorazepate (Tranxene®), diazepam (Valium®), estazolam (ProSom®), flurazepam (Dalmane®), lorazepam (Ativan®), oxazepam (Serax®), prazepam (Centrax®), temazepam (Restoril®).
    [Show full text]
  • Effects of Benzodiazepines on Sleep and Wakefulness
    Br. J. clin. Pharmac. (1981), 11, 31S-35S EFFECTS OF BENZODIAZEPINES ON SLEEP AND WAKEFULNESS T. ROTH, F. ZORICK, JEANNE SICKLESTEEL & E. STEPANSKI Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan The differential effects of short and long acting benzodiazepines on sleeping and waking behaviour are discussed, with particular reference to hypnotic efficacy, and their effects on the structure ofsleep and daytime function. Introduction THE evaluation of any drug requires an understand- et al., 1979), and triazolam (Metzler et al., 1977) have ing of the conditions in which it is going to be used come into clinical use. The present report will present clinically. In the case of hypnotics, the most appro- the differential effects of short- and long-acting ben- priate use is symptomatic relief for the complaint of zodiazepines on sleeping and waking behaviour. insomnia. To understand fully the safety and efficacy ofthese drugs, we must first be aware of the constella- tion of symptoms associated with the complaint of Sleep parameters insomnia, as well as what these drugs do to each of these symptoms. In evaluating the effects of hypnotics on sleep, two Insomnia is a complaint. Although all of the types of parameters should be considered. The first aetiological factors which give rise to this symptom set of parameters deal with hypnotic efficacy and are not currently well understood, there is an accepted include measures such as latency to sleep onset, total diagnostic system for the various disorders associated sleep time, number and duration of awakenings, and with disturbed nocturnal sleep (Association of Sleep sleep efficiency.
    [Show full text]
  • Comparison of Short-And Long-Acting Benzodiazepine-Receptor Agonists
    J Pharmacol Sci 107, 277 – 284 (2008)3 Journal of Pharmacological Sciences ©2008 The Japanese Pharmacological Society Full Paper Comparison of Short- and Long-Acting Benzodiazepine-Receptor Agonists With Different Receptor Selectivity on Motor Coordination and Muscle Relaxation Following Thiopental-Induced Anesthesia in Mice Mamoru Tanaka1, Katsuya Suemaru1,2,*, Shinichi Watanabe1, Ranji Cui2, Bingjin Li2, and Hiroaki Araki1,2 1Division of Pharmacy, Ehime University Hospital, Shitsukawa, Toon, Ehime 791-0295, Japan 2Department of Clinical Pharmacology and Pharmacy, Neuroscience, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 791-0295, Japan Received November 7, 2007; Accepted May 15, 2008 Abstract. In this study, we compared the effects of Type I benzodiazepine receptor–selective agonists (zolpidem, quazepam) and Type I/II non-selective agonists (zopiclone, triazolam, nitrazepam) with either an ultra-short action (zolpidem, zopiclone, triazolam) or long action (quazepam, nitrazepam) on motor coordination (rota-rod test) and muscle relaxation (traction test) following the recovery from thiopental-induced anesthesia (20 mg/kg) in ddY mice. Zolpidem (3 mg/kg), zopiclone (6 mg/kg), and triazolam (0.3 mg/kg) similarly caused an approximately 2-fold prolongation of the thiopental-induced anesthesia. Nitrazepam (1 mg/kg) and quazepam (3 mg/kg) showed a 6- or 10-fold prolongation of the anesthesia, respectively. Zolpidem and zopiclone had no effect on the rota-rod and traction test. Moreover, zolpidem did not affect motor coordination and caused no muscle relaxation following the recovery from the thiopental-induced anesthesia. However, zopiclone significantly impaired the motor coordination at the beginning of the recovery. Triazolam significantly impaired the motor coordination and muscle relaxant activity by itself, and these impairments were markedly exacerbated after the recovery from anesthesia.
    [Show full text]
  • Residual Effects of Sleep Medication on Driving Ability
    Sleep Medicine Reviews (2004) 8, 309–325 www.elsevier.com/locate/smrv CLINICAL REVIEW Residual effects of sleep medication on driving ability Joris C. Verster*, Dieuwke S. Veldhuijzen, Edmund R. Volkerts Department of Psychopharmacology, Utrecht Institute for Pharmaceutical Sciences, University of Utrecht, PO Box 80082, 3508 TB, Utrecht, The Netherlands KEYWORDS Summary Most patients using hypnotics are ambulatory and presumably have a job and Zaleplon; Zolpidem; drive a car. Since driving a car is one of the most common but potentially dangerous Zopiclone; daily activities, hypnotics should act rapidly when needed, but daytime sleepiness and Benzodiazepine; other residual effects that may impair performance are unwanted. This review Hypnotics; Insomnia; summarizes the effects of hypnotics on driving ability as determined with the on-the- Driving; Sedation road driving test during normal traffic. Supportive evidence from epidemiological data, and results from driving simulators and closed-road studies are also considered. On-the-road studies revealed that benzodiazepine hypnotics significantly impaired driving ability the morning following bedtime administration. Impairment was sometimes also significant in the afternoon (16–17 h after administration). Similar driving impairment was observed with zopiclone. However, the magnitude of impairment depends on various factors including the half-life and dosage of the drug, and the time after administration. The results from on-the-road driving studies are supported by evidence obtained in driving simulators and laboratory tests. Epidemiological data and on-the-road studies show that tolerance develops to the impairing effects of hypnotics. However, this is a slow process, and impairment may persist. Patients treated with benzodiazepine hypnotics or zopiclone should be cautioned when driving a car.
    [Show full text]
  • CNS Drug Reviews Vol
    CNS Drug Reviews Vol. 10, No. 1, pp. 45–76 © 2004 Neva Press, Branford, Connecticut Clinical Pharmacology, Clinical Efficacy, and Behavioral Toxicity of Alprazolam: A Review of the Literature Joris C. Verster and Edmund R. Volkerts Utrecht Institute for Pharmaceutical Sciences, Department of Psychopharmacology, University of Utrecht, Utrecht, The Netherlands Keywords: Alprazolam — Benzodiazepines — Anxiety — Depression — Panic — Sedation. ABSTRACT Alprazolam is a benzodiazepine derivative that is currently used in the treatment of generalized anxiety, panic attacks with or without agoraphobia, and depression. Alprazo- lam has a fast onset of symptom relief (within the first week); it is unlikely to produce de- pendency or abuse. No tolerance to its therapeutic effect has been reported. At discontinu- ation of alprazolam treatment, withdrawal and rebound symptoms are common. Hence, alprazolam discontinuation must be tapered. An exhaustive review of the literature showed that alprazolam is significantly superior to placebo, and is at least equally effective in the relief of symptoms as tricyclic antide- pressants (TCAs), such as imipramine. However, although alprazolam and imipramine are significantly more effective than placebo in the treatment of panic attacks, Selective Sero- tonin Reuptake Inhibitors (SSRIs) appear to be superior to either of the two drugs. Therefore, alprazolam is recommended as a second line treatment option, when SSRIs are not effective or well tolerated. In addition to its therapeutic effects, alprazolam produces adverse effects, such as drowsiness and sedation. Since alprazolam is widely used, many clinical studies investi- gated its cognitive and psychomotor effects. It is evident from these studies that alprazo- lam may impair performance in a variety of skills in healthy volunteers as well as in pa- tients.
    [Show full text]
  • The Role of A6 Subunit-Containing GABAA Receptors in Behavioral
    OLGA Yu VEKOVISCHEVA The Role of a6 Subunit-containing GABA Receptors in Behavioral Effects of A Alcohol and Drug Treatments ACADEMIC DISSERTATION To be presented, with the permission of the Faculty of Medicine of the University of Tampere, for public discussion in the auditorium of Tampere School of Public Health, Medisiinarinkatu 3, Tampere, on May 23rd, 2003, at 12 oclock Acta Universitatis Tamperensis 928 University of Tampere Tampere 2003 ACADEMIC DISSERTATION University of Tampere, Medical School University of Turku, Department of Pharmacology and Clinical Pharmacology Finland Supervised by Reviewed by Professor Esa R& Korpi Professor Sture Liljequist University of Helsinki Karolinska Institutet Docent Mikko Uusi-Oukari Docent Tomi Taira University of Turku University of Helsinki Professor Simo Oja University of Tampere Distribution University of Tampere Bookshop TAJU Tel +358 3 215 6055 PO Box 617 Fax +358 3 215 7685 33014 University of Tampere taju@utafi Finland http://granumutafi Cover design by Juha Siro Printed dissertation Electronic dissertation Acta Universitatis Tamperensis 928 Acta Electronica Universitatis Tamperensis 251 ISBN 951-44-5662-9 ISBN 951-44-5663-7 ISSN 1455-1616 ISSN 1456-954X http://actautafi Tampereen yliopistopaino Oy Juvenes Print Tampere 2003 3 CONTENTS CONTENTS 4 LIST OF ORIGINAL PUBLICATIONS 6 ABBREVIATIONS 7 ABSTRACT 8 1. INTRODUCTION 9 2. REVIEW OF THE LITERATURE 11 2.1. The inhibitory γ-aminobutyric acid system. General overview 11 2.2. GABAA receptors 12 2.2.1. Molecular biology of GABAA receptors 12 2.2.2. Diazepam as a classical benzodiazepine modulator of 14 GABAA receptors 2.2.3. Ethanol as a modulator of GABAA receptor function 15 2.3.
    [Show full text]
  • In the Treatment of Generalised Anxiety Disorder Does Pharmacology
    Characteristics Table for The Clinical Question: In the treatment of generalised anxiety disorder does 6/18/2010 12:21:10 pharmacology improve outcome? Comparisons Included in this Clinical Question Anticonvulsants versus Placebo Anticonvulsants vs Venlafaxine (SNRI) Antihistamine vs Placebo Benzodiazepines versus vs Placebo Anticonvulsants FELTNER2003 DARCIS1995 KASPER2009 KASPER2009 LADER1998 FELTNER2003 MONTGOMERY2006 MONTGOMERY2006 LLORCA2002 PANDE2003 MONTGOMERY2008 PFIZER2005 PANDE2003 RICKELS2005 PFIZER2005 POHL2005 RICKELS2005 Benzodiazepines versus Azapirones Benzodiazepines versus Placebo Buspirone vs Placebo Duloxetine (SNRI) vs. placebo BOURIN1992 ANDREATINI2002 DAVIDSON1999 HARTFORD2007 ANSSEAU2001 LADER1998 KOPONEN2007 CUTLER1993A MAJERCSIK2003 NICOLINI2009 FELTNER2003 POLLACK1997 RYNN2008 FRESQUET2000 SRAMEK1996 HACKETT2003 LYDIARD1997 MCLEOD1992 MOLLER2001 PANDE2003 PFIZER2008 RICKELS2000B RICKELS2005 Duloxetine (SNRI) vs. Venlafaxine Quetiapine versus Placebo SSRI vs Venlafaxine SSRIs versus Placebo (SNRI) ASTRAZENECA2007A BOSE2008 ALLGULANDER2004 HARTFORD2007 ASTRAZENECA2007B ASTRAZENECA2007A NICOLINI2009 ASTRAZENECA2007C ASTRAZENECA2007B ASTRAZENECA2008 BALDWIN2006 BOSE2008 BRAWMAN-MINTZER2006 DAVIDSON2004 GOODMAN2005 GSK2002 GSK2005 HEWETT2001 LENZE2005 LENZE2009 PFIZER2008 POLLACK2001 RICKELS2003 SSRIs versus SSRIs TCA vs Placebo Venlafaxine (SNRI) versus Azapirones Venlafaxine (SNRI) versus placebo BALDWIN2006 MCLEOD1992 DAVIDSON1999 ALLGULANDER2001 BALL2005 BOSE2008 BIELSKI2005 DAVIDSON1999 GELENBERG2000 HACKETT2003
    [Show full text]